Journal News

Flipping the switch

Courtney Chandler
Nov. 23, 2021

Eukaryotic cells must balance multiple factors before they can grow. The mechanistic target of rapamycin complex 1, or mTORC1, pathway senses and responds to various environmental cues, including nutrient availability, to control protein synthesis and cell growth.

The RagA–RagC GTPase heterodimer is required to activate mTORC1. Depending on amino acid availability, the RagA and RagC subunits will be oppositely loaded with either guanosine triphosphate or guanosine diphosphate, known as GTP and GDP. This variable nucleotide binding induces conformational changes in the heterodimer structure that promote the interaction or release of mTORC1.

When concentrations of amino acids in the cell are high, RagA is bound to GTP, and RagC is bound to GDP — this structural conformation facilitates mTORC1 interaction and activation of protein synthesis at the lysosomal surface. The reverse GTP/GDP loading leads to inhibition of mTORC1 and release from the lysosomal surface into the cytosol.

Until recently, researchers did not understand clearly how RagA and RagC maintain their oppositely nucleotide-loaded state to regulate mTORC1. In an article in the Journal of Biological Chemistry, a team from the University of Massachusetts Chan Medical School describes the molecular mechanism behind this regulation and the consequences of disrupting this balance.

Kuang Shen, an assistant professor at UMass and senior author on the article, described the RagA–RagC complex as a complicated light switch that controls mTORC1 — only when one switch is up and one switch is down will the mTORC1 lightbulb turn on.

“We were curious about the mechanism of regulation, because for us it’s like a black box and we didn’t understand how it worked,” Shen said.

Single-hydrogen-bond-890x376.jpg
Kuang Shen & Shawn Egri
A single hydrogen bond (in red in the box on the right) ensures the Rag GTPase complex can switch appropriately between the on and off states to regulate mTORC1 signaling and protein synthesis.

To peer into the black box, graduate student Shawn Egri used enzyme kinetics, structural biology and chemistry tools to probe the mechanism behind the regulation. Egri said he purified between 30 and 40 RagA–RagC mutants with individual amino acid differences and tested their activity one by one.

Eventually, the researchers identified mutants that eliminated normal RagA–RagC activity. They found that one interdomain hydrogen bond is all it takes to keep the switch in one position or the other and prevent it from spontaneously flipping between the two states.

“It was really amazing that just one hydrogen bond has this profound of an impact,” Shen said.

They next introduced mutants in which the interdomain hydrogen bond was broken (meaning the Rag GTPase cannot maintain its oppositely nucleotide-loaded state) into cells. They observed that with the interdomain hydrogen bond abolished, the GTPase subunits could not maintain their original nucleotide-loaded states in cells, leading to distorted responses to amino acid availability and altered mTORC1 interactions.

“It was surprising to us that our results (with purified proteins) translated so strongly in cells,” Egri said. “The phenotype was very clear even in wild-type cell background.”

In the future, Egri and Shen want to lock the complex in the on and off positions to see how that affects interactions with upstream regulators and downstream effectors of the mTORC1 pathway. This could help piece together a better idea of the signals and pathways that regulate the essential processes of protein synthesis and cell growth.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a careers columnist for ASBMB Today.

Related articles

From the journals: JBC
Ken Farabaugh
From the journals: JBC
Ken Farabaugh
From the journals: JBC
Ken Farabaugh
From the journals: JBC
Ken Farabaugh
From the journals: JBC
Ken Farabaugh

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The quest to treat and cure xerostomia
Interview

The quest to treat and cure xerostomia

July 23, 2024

Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.

There's more to blue cheese than just the stench
News

There's more to blue cheese than just the stench

July 21, 2024

Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.

Engineering cells to broadcast their behavior can help scientists study their inner workings
News

Engineering cells to broadcast their behavior can help scientists study their inner workings

July 20, 2024

Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.

From the journals: JBC
Journal News

From the journals: JBC

July 19, 2024

Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.